ABVX Stock Overview
A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.25 |
| 52 Week High | €15.42 |
| 52 Week Low | €4.51 |
| Beta | 1.56 |
| 1 Month Change | -8.22% |
| 3 Month Change | -13.93% |
| 1 Year Change | -62.92% |
| 3 Year Change | -74.76% |
| 5 Year Change | -70.51% |
| Change since IPO | -75.00% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does ABIVAX Société Anonyme (EPA:ABVX) Use Debt?
Apr 07
Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?
Oct 03Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?
Apr 24Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 07An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued
Dec 11Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 06A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary
Dec 31
Shareholder Returns
| ABVX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 15.1% | 4.8% | 5.9% |
| 1Y | -62.9% | -36.7% | -9.1% |
Return vs Industry: ABVX underperformed the French Biotechs industry which returned -35% over the past year.
Return vs Market: ABVX underperformed the French Market which returned -8.3% over the past year.
Price Volatility
| ABVX volatility | |
|---|---|
| ABVX Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.3% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: ABVX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ABVX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 69 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn’s disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| ABVX fundamental statistics | |
|---|---|
| Market cap | €332.76m |
| Earnings (TTM) | -€176.24m |
| Revenue (TTM) | €10.79m |
30.8x
P/S Ratio-1.9x
P/E RatioIs ABVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABVX income statement (TTM) | |
|---|---|
| Revenue | €10.79m |
| Cost of Revenue | €0 |
| Gross Profit | €10.79m |
| Other Expenses | €187.03m |
| Earnings | -€176.24m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jun 02, 2025
| Earnings per share (EPS) | -2.78 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,633.08% |
| Debt/Equity Ratio | 263.3% |
How did ABVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 04:31 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABIVAX Société Anonyme is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Eric Le Berrigaud | Bryan Garnier & Co |
| Julian Harrison | BTIG |